Paracrine Factors of Human Fetal MSCs Inhibit Liver Cancer Growth Through Reduced Activation of IGF-1R/PI3K/Akt Signaling

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death in the world. The multikinase inhibitor sorafenib only demonstrated marginal improvement in overall survival for advanced disease prompted the search for alternative treatment options. Human mesenchymal stem cells (MSC...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Molecular therapy Ročník 23; číslo 4; s. 746 - 756
Hlavní autoři: Yulyana, Yulyana, Ho, Ivy A W, Sia, Kian Chuan, Newman, Jennifer P, Toh, Xin Yi, Endaya, Berwini B, Chan, Jerry K Y, Gnecchi, Massimiliano, Huynh, Hung, Chung, Alexander Y F, Lim, Kiat Hon, Leong, Hui Sun, Iyer, Narayanan Gopalakrishna, Hui, Kam Man, Lam, Paula Y P
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States Elsevier Inc 01.04.2015
Elsevier Limited
Nature Publishing Group
Témata:
ISSN:1525-0016, 1525-0024, 1525-0024
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death in the world. The multikinase inhibitor sorafenib only demonstrated marginal improvement in overall survival for advanced disease prompted the search for alternative treatment options. Human mesenchymal stem cells (MSCs) have the ability to home to tumor cells. However, its functional roles on the tumor microenvironment remain controversial. Herein, we showed that conditioned media derived from human fetal MSC (CM-hfMSCs) expressed high level of the insulin growth factor binding proteins IGFBPs and can sequester free insulin-like growth factors (IGFs) to inhibit HCC cell proliferation. The inhibitory effect of IGFBPs on IGF signaling was further evident from the reduction of activated IGF-1R and PI3K/Akt, leading eventually to the induction of cell cycle arrest. We also demonstrated that CM-hfMSCs could enhance the therapeutic efficacy of sorafenib and sunitinib. To the best of our knowledge, this is the first report to show that CM-hfMSCs has a tumor-specific, antiproliferative effect that is not observed with normal human hepatocyte cells and patient-derived matched normal tissues. Our results thus suggest that CM-hfMSCs can provide a useful tool to design alternative/adjuvant treatment strategies for HCC, especially in related function to potentiate the effects of chemotherapeutic drugs.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
The first two authors shared cofirst authorship.
ISSN:1525-0016
1525-0024
1525-0024
DOI:10.1038/mt.2015.13